Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07575308 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB

Name: HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB — clinical trial record (NCT07575308)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: HMBeacon

StatusRecruiting

PhasePhase 2

SponsorAlnylam Pharmaceuticals

Started2026-07-30

View on ClinicalTrials.gov ↗

Amendment history

2026-09-19

Trial sites expanded: 4 → 11 locations

2026-08-11

Study Status, Contacts/Locations v4

Recruitment opened

Trial sites expanded: 1 → 4 locations

Start dateestimated 2026-07-31→confirmed 2026-07-30

2026-07-13

Study Status v3

Start date2026-06-30→2026-07-31

2026-06-11

Study Status v2

Start date2026-05-22→2026-06-30

2026-05-12

Study Status v1

Start date2026-05-05→2026-05-22

2026-05-04

Original filing

Alnylam Pharmaceuticals

31 trials monitored

See 5 trials at risk

The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB

Trial Details

NCT Number	NCT07575308
Lead Sponsor	Alnylam Pharmaceuticals
Conditions	Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)
Enrollment	24 participants
Start Date	2026-07-30
Primary Completion	2027-06-30 (estimated)
Study Completion	2028-11-29 (estimated)
Updated on ClinicalTrials.gov	2026-09-18